Hi! I’m Doug, the founder of Pace Pharmaceuticals. We’re developing drugs for neurological diseases.
We currently have two compound series undergoing IND-enabling studies for Alzheimer’s Disease and schizophrenia, respectively:
The world’s first selective small-molecule GalR1 antagonist for Alzheimer’s disease.
Selective M4 receptor agonist for schizophrenia.
Drug discovery is notoriously slow and expensive — but it doesn’t have to be. We’ve streamlined the discovery process to be 1000× cheaper than usual, allowing us to generate clinical-trial-ready drugs at unprecedented efficiency.
Our short-term target (1–2 years from now) is 10 clinical-stage drugs. Our long-term target (~10 years from now) is 1,000 clinical-stage drugs.
Pace Pharmaceuticals will pave the way for a new golden age of drug discovery.